default author photo

Prasad S. Kulkarni

Serum Institute of India Private Ltd

Pune

India

SCHOLARLY PAPERS

6

DOWNLOADS
Rank 40,456

SSRN RANKINGS

Top 40,456

in Total Papers Downloads

3,153

TOTAL CITATIONS

12

Scholarly Papers (6)

1.

A Phase III Randomised Controlled Trial Evaluating the Malaria Vaccine Candidate R21/Matrix-M™ in African Children

Number of pages: 25 Posted: 26 Sep 2023
University of Oxford - Centre for Clinical Vaccinology and Tropical Medicine, University of Sciences, Technique and Technologies of Bamako (USTTB) - Malaria Research and Training Centre, Institute de Recherche en Sciences de Santé (IRSS) - Clinical Research Unit of Nanoro, Institut des Sciences et Techniques (INSTech), Kenya Medical Research Institute (KEMRI) - Centre for Geographical Medicine Research -Coast (KEMRI-CGMRC), Ifakara Health Institute, London School of Hygiene & Tropical Medicine, University of Oxford - Centre for Clinical Vaccinology and Tropical Medicine, Institute de Recherche en Sciences de Santé (IRSS) - Clinical Research Unit of Nanoro, University of Oxford - Centre for Clinical Vaccinology and Tropical Medicine, Ifakara Health Institute, West African Network for Clinical Trials of Antimalarial Drugs (WANECAM), University of Sciences, Technique and Technologies of Bamako (USTTB) - Malaria Research and Training Centre, Institute de Recherche en Sciences de Santé (IRSS) - Clinical Research Unit of Nanoro, University of Oxford - KEMRI-Coast Centre for Geographical Medicine and Research, University of Oxford - Centre for Clinical Vaccinology and Tropical Medicine, Kenya Medical Research Institute (KEMRI) - Kemri-Wellcome Trust Research Programme, London School of Hygiene & Tropical Medicine, University of Oxford - Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford - Nuffield Department of Medicine, University of Oxford - The Jenner Institute, London School of Hygiene & Tropical Medicine, GSK plc, London School of Hygiene & Tropical Medicine, Serum Institute of India Private Ltd, Serum Institute of India Private Ltd, Serum Institute of India Private Ltd and University of Oxford - The Jenner Institute
Downloads 2,255 (16,677)
Citation 9

Abstract:

Loading...

malaria, vaccine, safety, efficacy, licensure trial, public health, low-cost, impact on childhood mortality

2.

A Phase 2/3, Observer-Blind, Randomised, Controlled Study to Assess the Safety and Immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 Vaccine) in Adults in India

Number of pages: 32 Posted: 09 Aug 2021
Serum Institute of India Private Ltd, Indian Council of Medical Research (ICMR)Indian Council of Medical Research (ICMR) - National Institute for Research in Tuberculosis, AstraZeneca Biopharmaceuticals, KEM Hospital Research Centre - Vadu Budruk, Post Graduate Institute of Medical Education & Research (PGIMER), JSS Academy of Higher Education and Research, Mahatma Gandhi Institute of Medical Sciences, Seth G S Medical College & KEM Hospital, B J Government Medical College and Sassoon General Hospitals, Bharati Vidyapeeth (Deemed to be University) - Department of Pediatrics, Jehangir Clinical Development Centre, Topiwala National Medical College & B. Y. L. Nair Hospital, Government Medical College, Directorate of Public Health and Preventive Medicine, Indian Council of Medical Research (ICMR) - Rajendra Memorial Research Institute of Medical Sciences, Andhra Medical College, Sri Ramchandra Institute of Higher Education and Research, Serum Institute of India Private Ltd, Serum Institute of India Private Ltd, PPD India Pvt Ltd, PPD Laboratories Inc, - Vaccine Sciences Department, Indian Council of Medical Research (ICMR), Indian Council of Medical Research (ICMR), AstraZeneca Pharmaceuticals - AstraZeneca R&D, Serum Institute of India Private Ltd, Indian Council of Medical Research (ICMR), Indian Council of Medical Research (ICMR), Indian Council of Medical Research (ICMR), Serum Institute of India Private Ltd, Serum Institute of India Private Ltd, Serum Institute of India Private Ltd and Independent
Downloads 378 (195,842)
Citation 1

Abstract:

Loading...

3.

Safety and Immunogenicity of SII-NVX-CoV2373 (COVID-19 Vaccine) In Adults in a Phase 2/3, Observer-Blind, Randomised, Controlled Study

Number of pages: 31 Posted: 08 Jul 2022
Serum Institute of India Private Ltd, Indian Council of Medical Research (ICMR) - National AIDS Research Institute, Indian Council of Medical Research (ICMR) - National AIDS Research Institute, Dr. D. Y. Patil Medical College, Hospital & Research Centre - Dr. D. Y. Patil Medical College, Hospital & Research Centre, Students, Mahatma Gandhi Institute of Medical Sciences, Hamdard Institute of Medical Sciences & Research (HIMSR), University of Liverpool - School of Tropical Medicine, JSS Academy of Higher Education and Research, Institute of Medical Sciences & SUM Hospital, KLES Dr. Prabhakar Kore Hospital & M.R.C, KEM Hospital Research Centre - Vadu Budruk, Seth G S Medical College & KEM Hospital, Government Medical College, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), KIIT University - Kalinga Institute of Medical Sciences (KIMS), KIMS Hospital and Research Centre, Christian Medical College, Sahyadri Super Specialty Hospital, Pune, Acharya Vinoba Bhave Rural Hospital, Amrita Institute of Medical Science - Division of Infectious Disease, Noble Hospital, All India Institute of Medical Sciences (AIIMS), Bhopal, All India Institute of Medical Sciences (AIIMS), Gorakhpur, Serum Institute of India Private Ltd, Serum Institute of India Private Ltd, Novavax, Inc. - Clinical Immunology Laboratory, Novavax, Inc. - Clinical Immunology Laboratory, Novavax, Inc. - Clinical Immunology Laboratory, 360biolabs, Indian Council of Medical Research (ICMR), Indian Council of Medical Research–National AIDS Research Institute, Serum Institute of India Private Ltd, Indian Council of Medical Research (ICMR), Indian Council of Medical Research (ICMR), Serum Institute of India Private Ltd, Serum Institute of India Private Ltd, Indian Council of Medical Research (ICMR), Serum Institute of India Private Ltd, Serum Institute of India Private Ltd and Independent
Downloads 163 (461,984)
Citation 1

Abstract:

Loading...

SII-NVX-CoV2373, NVX-CoV2373, safety, immunogenicity, non-inferiority

4.

Safety and Immunogenicity of a Bivalent Paratyphoid A-Typhoid Conjugate Vaccine in Healthy Indian Adults: A Phase I, Randomized, Active Controlled Study

Number of pages: 26 Posted: 28 Aug 2023
Serum Institute of India Private Ltd, Serum Institute of India Pvt Ltd, Serum Institute of India Private Ltd, Syngene International Limited, Syngene International Limited, Syngene International Limited, Serum Institute of India Private Ltd, Serum Institute of India Private Ltd, Serum Institute of India Private Ltd, Serum Institute of India Private Ltd, Serum Institute of India Private Ltd, Serum Institute of India Private Ltd, Serum Institute of India Private Ltd, Serum Institute of India Private Ltd, Emmes India Pvt, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group and Independent
Downloads 145 (508,926)
Citation 1

Abstract:

Loading...

Enteric fever, typhoid, paratyphoid, first-in-human

5.

Immunogenicity and Safety of Meningococcal ACWYX Conjugate Vaccine When Coadministered with Routine Childhood Vaccines at 9-Months and 15-Months of Age: A Randomised, Controlled, Phase 3, Non-Inferiority Trial

Number of pages: 41 Posted: 08 Oct 2024
Centre pour le Développement des Vaccins (CVD-Mali), Centre pour le Développement des Vaccins (CVD-Mali), - Department of Pediatrics, Centre pour le Développement des Vaccins (CVD-Mali), Centre pour le Développement des Vaccins (CVD-Mali), Centre pour le Développement des Vaccins (CVD-Mali), Centre pour le Développement des Vaccins (CVD-Mali), Centre pour le Développement des Vaccins (CVD-Mali), Fred Hutchinson Cancer Research Center, - Center for Vaccine Development and Global Health, PATH, PATH, PATH, PATH, Serum Institute of India Private Ltd, Serum Institute of India Private Ltd, UK Health Security Agency, VisMederi SRL, Emory University - School of Medicine, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center, Government of Mali - Centre pour le Développement des Vaccins, - Department of Pediatrics and University of Maryland School of Medicine - Center for Vaccine Development and Global Health
Downloads 140 (534,155)

Abstract:

Loading...

Meningitis, Vaccine, Phase 3

6.

Immunogenicity and Safety of a Meningococcal A Conjugate Vaccine Administered with Routine EPI Vaccines in African Infants and Toddlers

Number of pages: 41 Posted: 06 Jun 2025
Ghana Health Service, Centre pour le Développement des Vaccins (CVD-Mali), Government of Mali - Centre pour le Développement des Vaccins, Navrongo Health Research Centre (NHRC), Navrongo Health Research Centre (NHRC), - Department of Pediatrics, Navrongo Health Research Centre (NHRC), World Health Organization (WHO), PATH, GSK Vaccines Institute for Global Health, University of Siena, University of Siena, PATH, U.S. Centers for Disease Control and Prevention, DiagnoSearch Life Sciences, PATH, PATH, PATH, Serum Institute of India Private Ltd, U.S. Centers for Disease Control and Prevention, Meningococcal Reference Unit, UK Health Security Agency, PATH and World Health Organization (WHO)
Downloads 72 (867,774)

Abstract:

Loading...

bacterial meningitis, meningococcal conjugate vaccine, serogroup A, African meningitis belt